Catamaran Bio 1232 followers on LinkedIn.

Catamaran bio inc. Catamaran is supported by a syndicate of leading life science investors who share a deep commitment to discovering and developing transformative cell therapies. Shih is an experienced biopharma executive with a. Technical scientific consultation or product development for others in the fields of biotechnology cell therapy and development of pharmaceuticals and.

CAMBRIDGE MassCatamaran Bio Inc a biotechnology company developing allogeneic CAR-NK cell therapies to treat diseases with significant unmet medical need announced the appointment of Alvin Shih MD MBA as President and Chief Executive Officer. Based biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer launched with. Subscribe to Catamaran Bio.

CAMBRIDGE Mass--BUSINESS WIRE--Catamaran Bio Inc a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer today announced that the company has launched with 42. Catamaran Bio Announces Appointment of Dr. Cell therapy company developing allogeneic off-the-shelf products for patients with high unmet medical need At Catamaran our mission is to harness.

Alvin Shih as President and Chief Executive Officer. Catamaran Bio is developing novel off-the-shelf CAR-NK cell therapies designed to treat a broad range of cancers including solid tumors. April 2 2020 pharmaceutical preparations and therapeutic agents for the treatment of diseases and conditions namely cancer and immune Owned by.

Shih is an experienced biopharma executive with a track record of. Alvin Shih as President and Chief Executive Officer. Preclinical studies confirm that the biological features we are engineering into our CAR-NK cell therapies result in profound effects against solid tumors as well as hematologic malignancies.

3900 CO SV HEALTH INVESTORS BOSTON MA 02108. Other programs in our pipeline include potency-boosted CAR-NK cell therapies to address solid tumors that express novel surface markers. Vedere Bio ll Inc.